Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival

摘要

Background: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% of the patients experience further progression. With a focus on the pre- and post-SRT serum level of the prostate-specific antigen (PSA), we assessed the determinants of the long-term outcome after SRT.Patient and methods: Between 1997 and 2011, 464 patients received 3D-conformal SRT with median 66.6Gy. The median PSA level before SRT was 0.31ng/ml. In our retrospective analysis, post-SRT progression was defined as either a rising PSA 0.2ng/ml above the nadir, or the application of anti-androgens or clinical recurrence. A PSA 0.1ng/ml was termed undetectable. We analyzed the data with the Kaplan-Meier method (Logrank test) and multivariable Cox regression.Results: The median follow-up was 5.9 years. Overall, 178 patients had recurrence, 13 developed distant metastases and 30 died. Univariate, a pre-RP PSA 10ng/ml, pathological stage pT 3, Gleason score 8, positive surgical margins, a pre-SRT PSA 0.2ng/ml and a post-SRT PSA nadir 0.1ng/ml correlated with fewer and later second recurrences. In a multivariable Cox model, pT, Gleason score, margin status and pre-SRT PSA were significant covariates of progression. If the post-SRT PSA response was included in the regression analysis, then a nadir 0.1ng/ml was the strongest risk factor. Initiating SRT at a PSA 0.2ng/ml correlated with a post-SRT PSA 0.1ng/ml. Men who achieved an undetectable post-SRT PSA nadir also had lower rates of metastases and a better overall survival. However, there were too few events for Cox regression analysis of these two endpoints.Conclusions: Early SRT at a PSA 0.2ng/ml correlates with re-achieving an undetectable PSA, which predicts improved freedom from progression and metastases and better overall survival.